Dynavax’ Heplisav Phase III Data Bolsters Hep B Seroprotection Claims
Long-term data from study comparing Heplisav to GSK's Engerix-B shows 100 percent seroprotection 50 weeks post-vaccination.
Long-term data from study comparing Heplisav to GSK's Engerix-B shows 100 percent seroprotection 50 weeks post-vaccination.